1. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration
- Author
-
Shuntaro Yabe, Takeshi Tomoda, Kazuyuki Matsumoto, Daisuke Uchida, Yosuke Saragai, Saimon Takada, Soichiro Ako, Shinichiro Muro, Hideaki Kinugasa, Hironari Kato, Kazuhiro Nouso, Shigeru Horiguchi, and Hiroyuki Okada
- Subjects
Male ,Endoscopic ultrasound ,medicine.medical_specialty ,Physiology ,DNA Mutational Analysis ,medicine.disease_cause ,Polymerase Chain Reaction ,Risk Assessment ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,Pancreatectomy ,0302 clinical medicine ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,Pancreatic cancer ,Biomarkers, Tumor ,medicine ,Humans ,Digital polymerase chain reaction ,Endoscopic Ultrasound-Guided Fine Needle Aspiration ,neoplasms ,Pathological ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Reproducibility of Results ,Middle Aged ,Hepatology ,medicine.disease ,digestive system diseases ,Pancreatic Neoplasms ,KRAS Mutation Analysis ,Fine-needle aspiration ,030220 oncology & carcinogenesis ,Mutation ,Female ,030211 gastroenterology & hepatology ,KRAS ,Radiology ,Neoplasm Recurrence, Local ,business - Abstract
The sensitivity of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for diagnosing the recurrence of pancreatic cancer is usually low because of difficulties in obtaining adequate samples for pathological examinations. We evaluated the efficacy of highly sensitive KRAS mutation analysis using EUS-FNA washes to detect cancer recurrence. Nineteen consecutive patients with suspected pancreatic cancer recurrence after surgical resection were enrolled. All underwent EUS-FNA, and samples were obtained for pathological examination. After the first session, the inside of the FNA needle was washed with saline for DNA extraction. KRAS mutations were examined using digital droplet PCR (dPCR). The median needle puncture number used to obtain adequate pathological samples was two (range 1–6). In ten patients pathologically diagnosed with malignant pancreatic cancer, nine patients tested positive for a KRAS mutation. All patients who were not diagnosed with a malignant pancreatic cancer tested negative for a KRAS mutation. About half of surgically resected primary cancers (9/19) showed double KRAS mutations (G12V and G12D); however, all but one wash sample showed a single KRAS mutation, G12D. After including one patient who showed a malignant recurrence during follow-up, the sensitivities of a pathological diagnosis and KRAS analysis to detect recurrence were 90.9% and 81.8%, respectively. KRAS mutation analysis of needle wash samples using dPCR is a new methodology for the diagnosis of the local recurrence of pancreatic cancer. The diagnostic ability of dPCR with a one-time needle wash sample was comparable to a pathological diagnosis with multiple samplings.
- Published
- 2020